Stockscreener 앱 받기
7.32
0.97%
0.07
시간 외 거래:
7.42
0.10
+1.37%
전일 마감가:
$7.25
열려 있는:
$7.28
하루 거래량:
5.72M
Relative Volume:
1.35
시가총액:
$1.54B
수익:
$557.51M
순이익/손실:
$-35.71M
주가수익비율:
-40.67
EPS:
-0.18
순현금흐름:
$15.50M
1주 성능:
+1.67%
1개월 성능:
-3.56%
6개월 성능:
-17.29%
1년 성능:
-8.61%
1일 변동 폭
$7.18
$7.47
1주일 범위
$7.17
$7.47
52주 변동 폭
$6.00
$11.31
바이오크리스트 Stock (BCRX) Company Profile
명칭
Biocryst Pharmaceuticals Inc
전화
919-859-1302
주소
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
7.32 | 1.53B | 557.51M | -35.71M | 15.50M | -0.18 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
바이오크리스트 Stock (BCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-15 | 재개 | TD Cowen | Buy |
| 2025-10-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 개시 | Wedbush | Outperform |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-09-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-02-22 | 업그레이드 | Needham | Hold → Buy |
| 2022-11-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-08-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-04-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-10 | 개시 | Oppenheimer | Outperform |
| 2021-08-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 개시 | Cowen | Outperform |
| 2020-09-29 | 재개 | JP Morgan | Overweight |
| 2020-06-17 | 개시 | BTIG Research | Neutral |
| 2020-05-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-15 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 재개 | Piper Jaffray | Overweight |
| 2018-08-08 | 재개 | JP Morgan | Overweight |
| 2018-07-17 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 개시 | Seaport Global Securities | Neutral |
| 2018-01-02 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 개시 | Barclays | Equal Weight |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-09-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-02-16 | 개시 | Ladenburg Thalmann | Buy |
| 2016-08-12 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | FBR Capital | Outperform |
| 2016-02-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-02-09 | 다운그레이드 | Needham | Buy → Hold |
모두보기
바이오크리스트 주식(BCRX)의 최신 뉴스
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyGlobal Markets & Reliable Intraday Trade Plans - newser.com
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackEarnings Miss & Daily Profit Focused Stock Screening - newser.com
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Momentum Check & Smart Swing Trading Techniques - newser.com
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutEarnings Risk Summary & Real-Time Price Movement Reports - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Short Interest & Verified Technical Signals - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investorsMarket Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolutionWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com
BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq
BioCryst Pharmaceuticals Inc.’s volatility index tracking explainedJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why BioCryst Shares Plunged - AOL.com
Aug Shorts: Why hedge funds are buying BioCryst Pharmaceuticals Inc. stockTrade Entry Report & Weekly Stock Performance Updates - Fundação Cultural do Pará
When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - newser.com
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - sharewise.com
Will BioCryst Pharmaceuticals Inc. stock outperform international peersPortfolio Update Report & AI Optimized Trading Strategy Guides - Fundação Cultural do Pará
BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Monday - MarketBeat
바이오크리스트 (BCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오크리스트 주식 (BCRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director |
Aug 13 '25 |
Sale |
8.51 |
70,000 |
595,868 |
65,352 |
3.18%
1.86%
자본화:
|
볼륨(24시간):